PRESS RELEASES

Date	Title
Nov 10, 2020	Ardelyx to Present at the Jefferies Virtual London Healthcare Conference
Nov 6, 2020	Ardelyx to Webcast Virtual Analyst Day
Nov 5, 2020	Ardelyx Reports Third Quarter 2020 Financial Results and Business Highlights
Oct 22, 2020	Ardelyx and Kyowa Kirin Highlight New Data Supporting the Clinical Safety and Efficacy of First-In-Class, Phosphate Absorption Inhibitor Tenapanor at ASN's Kidney Week 2020
Oct 22, 2020	Ardelyx Launches 'Can We Do Better?' Campaign at ASN's Kidney Week 2020
Oct 12, 2020	Ardelyx Announces Data Supporting Efficacy and Safety of Tenapanor, a First-in-Class Phosphate Absorption Inhibitor, to be Presented at ASN's Kidney Week 2020
Sep 15, 2020	Ardelyx Announces FDA Acceptance for Filing of its New Drug Application of Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis
Sep 8, 2020	Ardelyx to Participate in Three Upcoming Investor Conferences in September
Aug 6, 2020	Ardelyx Reports Second Quarter 2020 Financial Results and Recent Business Highlights
Aug 3, 2020	Ardelyx Selected as a Finalist in the Fierce Innovation Awards for the Development of its First-in-Class Product Candidate Tenapanor

FAQs

Email Alerts

Connect

Bay Area
34175 Ardenwood Boulevard
Fremont, CA 94555

Boston Area
200 West Street, 4th Floor
Waltham, MA 02451

Phone: 510.745.1700

Inquiries:
General: info@ardelyx.com
Media: media@ardelyx.com
Investor: investor@ardelyx.com
Business Development: partnering@ardelyx.com